Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Common blood tests for liver disease.

Neuschwander-Tetri BA.

Postgrad Med. 1995 Jul;98(1):49-63. doi: 10.1080/00325481.1995.11946016.

PMID:
29224482
2.

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721. [Epub ahead of print] Review.

PMID:
29222917
3.

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724. [Epub ahead of print] Review.

PMID:
29222911
4.

Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science.

Shadab Siddiqui M, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman S, Greene K, Kleiner D, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group.

Hepatology. 2017 Oct 23. doi: 10.1002/hep.29607. [Epub ahead of print]

PMID:
29059456
5.

Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.

Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ, Chalasani N; NASH Clinical Research Network.

Hepatology. 2017 Aug 31. doi: 10.1002/hep.29489. [Epub ahead of print]

PMID:
28859228
6.

Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.

Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrota D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, Miller V; Liver Forum’s Data Standardization Working Group.

Gastroenterology. 2017 Sep;153(3):621-625.e7. doi: 10.1053/j.gastro.2017.07.024. Epub 2017 Jul 27. No abstract available.

PMID:
28757264
7.

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.

Barritt AS 4th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A.

Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.

PMID:
28735109
8.

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.

Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB; NASH Clinical Research Network.

Gastroenterology. 2017 Sep;153(3):753-761. doi: 10.1053/j.gastro.2017.06.005. Epub 2017 Jun 15.

PMID:
28624576
9.

Brown adipose tissue detected by PET/CT imaging is associated with less central obesity.

Green AL, Bagci U, Hussein S, Kelly PV, Muzaffar R, Neuschwander-Tetri BA, Osman MM.

Nucl Med Commun. 2017 Jul;38(7):629-635. doi: 10.1097/MNM.0000000000000691.

PMID:
28509766
10.

Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.

Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

J Pediatr. 2017 Aug;187:141-146.e1. doi: 10.1016/j.jpeds.2017.03.007. Epub 2017 Mar 30.

PMID:
28366357
11.

Non-alcoholic fatty liver disease.

Neuschwander-Tetri BA.

BMC Med. 2017 Feb 28;15(1):45. doi: 10.1186/s12916-017-0806-8. Review.

12.

Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.

Cai CX, Buddha H, Castelino-Prabhu S, Zhang Z, Britton RS, Bacon BR, Neuschwander-Tetri BA.

Dig Dis Sci. 2017 Apr;62(4):968-978. doi: 10.1007/s10620-017-4470-9. Epub 2017 Feb 13.

PMID:
28194671
13.

Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice.

Ulmasov B, Neuschwander-Tetri BA, Lai J, Monastyrskiy V, Bhat T, Yates MP, Oliva J, Prinsen MJ, Ruminski PG, Griggs DW.

Cell Mol Gastroenterol Hepatol. 2016 Mar 16;2(4):499-518. doi: 10.1016/j.jcmgh.2016.03.004. eCollection 2016 Jul.

14.

Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.

Rotman Y, Neuschwander-Tetri BA.

Hepatology. 2017 Apr;65(4):1088-1090. doi: 10.1002/hep.29094. Epub 2017 Mar 3. No abstract available.

PMID:
28152575
15.

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; NASH CRN.

Gastroenterology. 2016 Dec;151(6):1141-1154.e9. doi: 10.1053/j.gastro.2016.08.027. Epub 2016 Aug 26.

16.

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, Noureddin M, Schiano TD, Siddiqui M, Sanyal A, Neuschwander-Tetri BA, Traber PG.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1183-1198. doi: 10.1111/apt.13816. Epub 2016 Oct 24.

PMID:
27778367
17.

Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Uc A, Andersen DK, Bellin MD, Bruce JI, Drewes AM, Engelhardt JF, Forsmark CE, Lerch MM, Lowe ME, Neuschwander-Tetri BA, OʼKeefe SJ, Palermo TM, Pasricha P, Saluja AK, Singh VK, Szigethy EM, Whitcomb DC, Yadav D, Conwell DL.

Pancreas. 2016 Nov;45(10):1365-1375.

18.

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1253-1264. doi: 10.1111/apt.13824. Epub 2016 Oct 11.

19.

Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, Klair J, Terrault NA, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A; Nonalcoholic Steatohepatitis Clinical Research Network.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):127-131.e2. doi: 10.1016/j.cgh.2016.07.034. Epub 2016 Aug 12.

PMID:
27523635
20.

Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition.

Jain AK, Sharma A, Arora S, Blomenkamp K, Jun IC, Luong R, Westrich DJ, Mittal A, Buchanan PM, Guzman MA, Long J, Neuschwander-Tetri BA, Teckman J.

JPEN J Parenter Enteral Nutr. 2017 Feb;41(2):198-207. doi: 10.1177/0148607116661838. Epub 2016 Aug 20.

PMID:
27503935

Supplemental Content

Loading ...
Support Center